Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Addition of Trastuzumab to Chemo Boosts Survival in HER2+ Uterine Serous Carcinoma

April 10th 2020

The addition of trastuzumab to carboplatin and paclitaxel resulted in a significant survival benefit in women with advanced or recurrent, HER2-positive uterine serous carcinoma, with the greatest benefit observed in those with stage III/IV disease who received the regimen up front.

Dr. Fader on Adding Trastuzumab to Chemo in HER2+ Uterine Serous Carcinoma

April 9th 2020

Amanda Nickles Fader, MD, discusses findings from a randomized phase II trial examining the efficacy of adding trastuzumab to carboplatin/paclitaxel in patients with advanced or recurrent uterine serous carcinomas that overexpress HER2/neu.

Dr. Gunderson on the Use of PARP Inhibitors in All-Comers With Ovarian Cancer

April 9th 2020

Camille C. Gunderson, MD, assistant professor of gynecologic oncology, Stephenson Cancer Center, discusses the use of PARP inhibitors in all-comers with ovarian cancer.

Palliative Care Study Suggests Benefits for Patients With Cervical Cancer

April 9th 2020

Alexandra S. Bercow, MD, discusses the implications of research showing that patients with advanced-stage cervical cancer who received palliative care consultations underwent the same level of treatment but had shorter, less acute, and fewer hospital stays than their counterparts who were not given such referrals.

Pazopanib Plus Oral Cyclophosphamide Shows Benefit in Platinum-Resistant Epithelial Ovarian Cancer

April 9th 2020

Pazopanib plus oral cyclophosphamide is a well-tolerated regimen that has clinically relevant benefit in patients with platinum-resistant or -refractory epithelial ovarian cancer, according to results from a retrospective study published in the Journal of Clinical Oncology.

FDA Grants Balstilimab Fast Track Designation for Cervical Cancer

April 8th 2020

The FDA has granted the PD-1 inhibitor balstilimab a Fast Track Designation for the treatment of patients with cervical cancer.

Dr. Coffman on Safety Concerns With PARP Inhibitors in Ovarian Cancer

April 7th 2020

Lan G. Coffman, MD, PhD, assistant professor at the University of Pittsburgh Medical (UPMC) Center Hillman Cancer Center, discusses safety concerns with PARP inhibitors in ovarian cancer.

Unique Aspects of Cancer Surgery Make Clinical Trials Challenging

April 7th 2020

The conduct of randomized trials in surgical oncology, although highly appealing in concept, may be problematic, especially in complex settings where the skills, experience, and clinical judgment of individual surgeons and their institutions may vary greatly.

Dr. Penson on Re-Challenging With PARP Inhibition in Ovarian Cancer

April 4th 2020

Richard T. Penson, MD, MRCP, associate professor of medicine, Harvard Medical School, and clinical director of Medical Gynecologic Oncology, in the Department of Medicine, Massachusetts General Hospital, discusses re-challenging with PARP inhibition in patients with ovarian cancer.

Dr. Brown on Germline and Somatic Testing in Ovarian Cancer

April 2nd 2020

Jubilee Brown, MD, discusses germline and somatic testing in ovarian cancer.

Investigators Seek to Improve SOC in Cervical Cancer

April 1st 2020

Motivated to move the needle in cervical cancer, investigators are adding durvalumab to standard-of-care concurrent chemoradiation therapy and brachytherapy to determine whether PD-L1 blockade is a key to improving survival outcomes.

Dr. Moore on Safety Profile of Mirvetuximab Soravtansine in Ovarian Cancer

March 27th 2020

Kathleen Moore, MD, discusses the safety profile of mirvetuximab soravtansine, an antibody-drug conjugate that targets the FRα transmembrane protein, in ovarian cancer.

VB-111 Hits Milestone in Phase III Platinum-Resistant Ovarian Cancer Trial

March 27th 2020

An independent panel determined that the investigational agent VB-111 met the interim prespecified efficacy criterion in the phase III OVAL study in patients with platinum-resistant ovarian cancer, and that the trial should continue without modification.

Racial Disparities Reported With Quality of Care in Endometrial Cancer

March 26th 2020

Jason D. Wright, MD, discusses the findings of this trial and how practice can shift to decrease the gap between African-American and white patients with endometrial cancer.

Dr. Mirza on the ENGOT-OV42-NSGO/AVANOVA-Triplet Trial in Recurrent Ovarian Cancer

March 25th 2020

Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology in Rigshospitalet, Copenhagen University Hospital, discusses the planned phase III ENGOT-OV42-NSGO/AVANOVA trial in platinum-sensitive, recurrent ovarian cancer.

Dr. Dizon on Potential Challenges for Patients With Gynecologic Cancers

March 19th 2020

Don S. Dizon, MD, FACP, FASCO, discusses potential challenges for patients with gynecologic cancers.

AXL Kinase Becomes a Therapeutic Target in Its Own Right

March 17th 2020

Despite being implicated across the spectrum of cancer hallmarks, aberrant AXL signaling is just starting to emerge as a distinct anticancer target, with a growing focus on specific inhibitors as well as alternative novel drug designs.

Niraparib Takes Step Toward Chinese Approval for Frontline Maintenance in Ovarian Cancer

March 16th 2020

The China National Medical Products Administration has accepted a supplemental New Drug Application for niraparib for use as a frontline maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.

Dr. Ledermann on the Additive Effects of Olaparib and Bevacizumab in Ovarian Cancer

March 14th 2020

Jonathan A. Ledermann, BSc, MD, FRCP, discusses the additive effects of olaparib (Lynparza) and bevacizumab (Avastin) in advanced ovarian cancer.

Dr. Penson on Research With PARP Inhibitors in Ovarian Cancer

March 14th 2020

Richard T. Penson, MD, MRCP, discusses unexpected findings from the phase III SOLO3 trial and ongoing research with PARP inhibitors in ovarian cancer.